Prostate Cancer

Guest post by Tom McFarlane

Introduction

Until relatively recently, metastatic castrate resistant prostate cancer (mCRPC) was a disease with very few treatment options available. Patient options were limited to bisphosphonate use for bony metastases and, eventually, chemotherapy of somewhat questionable efficacy with docetaxel and/or mitoxantrone. Since 2010, there have been several promising agents which have emerged in both the pre-chemo and post-chemo settings in mCRPC which have demonstrated progression-free survival (PFS) and overall survival (OS)...Read more

by Amy Smith, as part of her Green Oncology series

Recently, I had the unique opportunity to collaborate with Dr. David Blackburn, a professor at the University of Saskatchewan, on a research project with a focus in patient adherence. We reviewed de-identified patient data from the Saskatchewan Cancer Agency (SCA) to assess compliance rates to an orally administered chemotherapy agent: abiraterone .

The Issue:

A shift is occurring in chemotherapy administration from...Read more